Showing results (951-960 of 3,376) with videos related to

Sort By:
Pageof 338
The Lancet. Oncology|February 22, 2011
Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trialJames Berenson, Robert Pflugmacher, Peter Jarzem, et al.
The Lancet. Oncology|February 12, 2011
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective studyJack Cuzick, Gregory P Swanson, Gabrielle Fisher, et al.
The Lancet. Oncology|January 25, 2011
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessmentSteven Christopher Smith, Alexander Spyridon Baras, Garrett Dancik, et al.
The Lancet. Oncology|December 4, 2010
Biomarkers to predict the clinical efficacy of bevacizumab in cancerAdrian M Jubb, Adrian L Harris
The Lancet. Oncology|December 18, 2010
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancerWendy De Roock, Veerle De Vriendt, Nicola Normanno, et al.
The Lancet. Oncology|June 12, 2010
Potential pitfalls in the design and reporting of clinical trialsMatthew R Sydes, Ruth E Langley
The Lancet. Oncology|July 9, 2010
Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trialSung-Bum Kang, Ji Won Park, Seung-Yong Jeong, et al.
The Lancet. Oncology|July 10, 2010
PET in women with high risk for breast or ovarian cancerEinat Even-Sapir, Moshe Inbar
The Lancet. Oncology|July 20, 2010
Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trialMonika Janda, Val Gebski, Alison Brand, et al.
The Lancet. Oncology|July 13, 2010
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisWendy De Roock, Bart Claes, David Bernasconi, et al.
Pageof 338